

MATERIAL CHANGE NOTICE SUBMISSION DETAILS

MCN Number	2026-01-06-1463
OHCA Review Start Date	January 15, 2026
Anticipated date (unless tolled per regulation) by which OHCA could waive cost and market impact review	March 23, 2026
Anticipated date (unless tolled per regulation) by which OHCA could determine cost and market impact review required	April 6, 2026

SUBMITTER**HEALTH CARE ENTITY CONTACT FOR PUBLIC INQUIRY**

Title	Mr.
First Name	James
Last Name	Herriott
Email Address	jherriott@exactsciences.com
Street Address	5505 Endeavor Lane
City	Madison
State	WI
Postal Code	53719

GENERAL

Business Name	Exact Sciences Corporation
Website	www.exactsciences.com
Ownership Type	Corporation
Tax Status	For-profit
Federal Tax ID	98-0206122
Description of Submitting Organization	Submitter is a leading provider of cancer screening and diagnostics tests. It helps patients and healthcare providers make timely, informed decisions before, during and after a cancer diagnosis. The company's growing product line includes well-established brands such as Cologuard and Oncotype DX, along with innovative solutions like the CancerGuard test for multi-cancer early detection and the Oncodetect test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes.
Health Care Provider	Yes

For Providers: Desc. of Capacity or Patients served in California	Exact provides cancer screening and diagnostics services to patients in the entire state of California. It owns a clinical lab in Redwood City, CA, and has 918 FTEs in California. Exact does not track the number of patients served but does track, and is providing in Exhibits 3, 4, and 5, test volume data.
---	--

LOCATIONS

Counties	All Counties
California licenses and numbers	<p>Exact Sciences Laboratories - Clinical and Public Health Laboratory License # CDS90000987</p> <p>Exact Sciences Laboratories, LLC - Clinical and Public Health Laboratory License # CDS00800491</p> <p>Genomic Health Inc. - Clinical and Public Health Laboratory License # CDF00011799</p> <p>Genomic Health, Inc. - Clinical and Public Health Laboratory License # CDS00800471</p> <p>PreventionGenetics, LLC - Clinical and Public Health Laboratory License # CDS00800542</p> <p>In addition, testing personnel working in the Genomic Health Inc - Redwood City lab are individually licensed by CA. These license numbers can be found in the "CA Licenses" tab of the attached Exhibit 1.</p>
Other States Served	AK; AL; AR; AZ; CO; CT; DC; DE; FL; GA; HI; IA; ID; IL; IN; KS; KY; LA; MA; MD; ME; MI; MN; MO; MS; MT; NC; ND; NE; NH; NJ; NM; NV; NY; OH; OK; OR; PA; RI; SC; SD; TN; TX; UT; VA; VT; WA; WI; WV; WY
Other state(s) licenses and numbers	<p>Health-care related license information for other states can be found at the links below:</p> <ul style="list-style-type: none"> - https://www.exactlabs.com/quality-and-compliance/licensing-and-accreditation - https://precisiononcology.exactsciences.com/licenses - https://www.preventiongenetics.com/laboratory-credentials
Primary Languages used when providing services	English

MATERIAL CHANGE

ADDITIONAL ENTITIES

Business Name	Description of the Organization	Ownership Type	Additional MCN Submission
Abbott Laboratories	Abbott Laboratories is an international company that manufactures and sells diagnostics, medical devices, nutritional products and branded generic pharmaceuticals. Abbott's Redwood Toxicology Laboratory, Alere Home Monitoring, and Quality Assured Services provide services in all counties in California. See MCN being submitted by Abbott for additional details.	Corporation	Yes

CRITERIA

A health care entity with annual revenue, as defined in section 97435(d) , of at least \$25 million or that owns or controls California assets of at least \$25 million, or;	Yes
A health care entity with annual revenue, as defined in section 97435(d) , of at least \$10 million or that owns or controls California assets of at least \$10 million and is a party to a transaction with any health care entity satisfying subsection (b)(1), or	Yes

CIRCUMSTANCES FOR FILING

The proposed fair market value of the transaction is \$25 million or more and the transaction concerns the provision of health care services.	Yes
The transaction is more likely than not to increase annual California-derived revenue of any health care entity that is a party to the transaction by either \$10 million or more or 20% or more of annual California-derived revenue at normal or stabilized levels of utilization or operation.	Yes
The transaction involves the sale, transfer, lease, exchange, option, encumbrance, or other disposition of 25% or more of the total California assets of the submitter(s).	Yes
The transaction involves a transfer or change in control, responsibility or governance of the Submitter. A transaction will directly or indirectly transfer control, responsibility, or governance in whole or in part of a material amount of the assets or operations of a health care entity to one or more entities if: <ul style="list-style-type: none"> (1) The transaction would result in the transfer of 25% or more of the voting power of the members of the governing body of a health care entity, such as by adding one or more members, substituting one or more members, or through any other type of arrangement, written or oral; or (2) The transaction would vest voting rights significant enough to constitute a change in control such as supermajority rights, veto rights, and similar provisions even if ownership shares or representation on a governing body are less than 25%; 	Yes

TRANSACTION DETAILS

Anticipated Date of Transaction Closure	4/6/2026
Description of the Transaction	Please see attached Exhibit 2.
Submitted to US Department of Justice or Federal Trade Commission?	Yes
Date of Submission	1/5/2026
Description of the Submission	HSR Filing
Submitted to Other Agency?	Yes
Date of Submission	1/6/2026
To Whom Submitted	MA Health Policy Commission, OR Health Authority, NY Department of Health, IN Attorney General
Description of Submission (Include Agency name(s) and State(s))	MA HPC Notice of Material Change Form, Notice of Material Change Transaction with OR HA, Material Transaction Notice with NY DOH, IN AG Notice
Subject to court proceeding	No
Description of current services provided and expected post-transaction impacts on health care services	Exact provides cancer screening and diagnostics tests to patients throughout the state of California. There are no expected post-transaction impacts on services provided. Exact does not collect demographics information related to the patients it serves. Payer information for Cologuard and Oncotype DX (IBC), which make up the vast majority of tests processed by Exact, is provided in the attached Exhibits 3 and 4. Medi-Cal and Medicare patients are currently accepted - no post-transaction changes thereto are expected. Exact does not conduct community needs assessments, offer charity care, or provide community benefit programs - no post-transaction changes thereto are expected.
Prior mergers or acquisitions that: (A) involved the same or related health care services; (B) involved at least one of the entities, or their parents, subsidiaries, predecessors, or successors, in the proposed transaction; and (C) were closed in the last ten years.	A summary of Exact's prior acquisitions since 2015 are provided in the attached Exhibit 6.

Description of Potential Post Transaction Changes	<p>Exact Sciences will continue to be operated as a stand-alone business, and there are no plans to integrate it with other Abbott businesses. As such, no structural ownership, governance, or operational changes are expected post-transaction. The parties do not anticipate any changes post-closing to employee staffing levels, job security or retaining policies, employee wages, benefits, working conditions, and employment protections. Exact Sciences will continue to be operated as a stand-alone business, and there are no plans to integrate it with the Abbott's toxicology or Acelis businesses. The parties do not anticipate changes to any contracts with cities or counties regarding the provision of any services following the closing of the transaction. Exact Sciences is not aware of any potential post-transaction changes to comparable health services offered by other health care entities within twenty (20) miles of any location where Exact Sciences offers services.</p>
Description of the nature, scope, and dates of any pending or planned material changes occurring between the Submitter and any other entity, within the 12 months following the date of the notice	<p>The submitter does not have any currently pending material change transactions. The parties do not anticipate any material change transactions between the submitted and any other entity that are planned to occur within 12 months following the date of the notice.</p>

Exhibit 2

Section 6 – Description of the Transaction

On November 19, 2025, Abbott Laboratories (NYSE: ABT) (“Abbott” or “Parent”) and Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences” or the “Seller”) entered into an Agreement and Plan of Merger (“Agreement”) for Abbott to acquire Exact Sciences through the merger of Abbott’s subsidiary, Badger Merger Sub I, Inc., with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Abbott (the “Proposed Transaction”). The parties entered into the Agreement to accelerate innovation and expand access to diagnostics focused on cancer screening, with a goal to help more people detect and manage cancer during its earliest stages. The transaction will enable Abbott to enter the fast-growing advanced cancer diagnostics segment, serving millions more people.

As described above, the Proposed Transaction will be effected via Badger Merger Sub I, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Parent, merging with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Parent. Exact Sciences shareholders will receive \$105 per common share, representing a total equity value of approximately \$21 billion. The transaction is expected to close in the second quarter of 2026, upon receipt of all required regulatory and shareholder approvals.

Together, Abbott and Exact Sciences will reach more patients to help prevent cancer, enable earlier detection, and empower physicians and consumers with data-driven insight that support more informed personalized care. Combined with Abbott’s global scale, reputation for operational and commercial excellence and strong relationships with healthcare systems, Exact Sciences will be positioned to create a powerful, new growth platform to unlock new opportunities to build upon in the future.

A combination of Abbott and Exact Sciences will expand the availability of advanced cancer diagnostic testing to reach new patient populations, both in the US and internationally, where Exact Sciences has limited presence today. Abbott’s research and development capabilities will also accelerate innovation in early cancer screening and precision oncology testing with Exact Sciences’ products to facilitate quicker turnaround times, lower costs, and improved patient experiences.

With this acquisition, Abbott hopes to enter the field of advanced cancer diagnostics, a large and rapidly growing segment. There is significant unmet clinical need in advanced cancer diagnostics as most preventable cancers go undetected and/or unscreened, and this transaction will broaden Abbott’s diagnostics capabilities across the cancer care continuum. By combining Abbott’s extensive research and development capabilities to develop instrument-based solutions for decentralized settings (e.g., physician offices, cancer centers) with Exact Sciences’ complementary suite of diagnostic products, the transaction would facilitate rapid turnaround times, lower costs, and improved patient access.

The transaction would also give Exact Sciences access to Abbott's strong international presence, thereby fostering improved access to important cancer testing options around the world and helping more people in more places.

This transaction is not a horizontal combination of competitors as Abbott and Exact Sciences do not compete today. Exact Sciences will continue to be operated as a stand-alone business and there are no current plans to integrate it with Abbott's toxicology or Acelis businesses. As a result, the parties do not anticipate adverse impacts of the transaction on the public. To the contrary, the parties expect the benefits set forth in the responses above.

Exhibit 3

COUNTY	Medicare	Med Adv	Commercial	MCO	Medicaid	Other Government	Self-Pay	Grand Total
*Unspecified	56		137	263	223	7	9	49 744
ADA					1			1
ALAMEDA	2,186		1,698	6,256	6,194	58	40	3,781 20,213
ALLEGHENY				1				1
ALPINE	10		2	8	4		1	25
AMADOR	253		145	316	75	4	5	21 819
BENEWAH			1					1
BROWARD				1				1
BUNCOMBE					1			1
BUTTE	1,496		331	1,847	896	11	7	175 4,763
CALAVERAS	501		145	543	181	5	1	29 1,405
CLARK			1	1				2
CLEARFIELD	1							1
COLUSA	124		28	143	170	8	1	35 509
CONTRA COSTA	1,897		1,255	5,939	1,199	22	37	855 11,204
DALLAS	1			2				3
DAVIDSON					1			1
DEKALB					1			1
DEL NORTE	147		17	134	147			10 455
DENTON	1							1
DESCHUTES				1				1
DEWEY				1				1
DISTRICT OF COLUMBIA				1				1
EL DORADO	935		544	2,076	387	19	23	276 4,260
ERIE					1			1
FAIRFIELD	1							1
FRANKLIN				1				1
FRESNO	1,323		2,360	3,872	1,266	33	41	290 9,185
GLENN	166		17	199	146	2	2	33 565
GRAYS HARBOR	1							1
GWINNETT					1			1
HARNEY	1							1
HAWAII				1				1
HONOLULU				1				1
HUMBOLDT	789		117	1,019	317	1	4	32 2,279
IMPERIAL	95		516	427	144		1	34 1,217
INYO	136		35	147	33	3		5 359
JACKSON					1			1
JOHNSON	1							1
JOHNSTON			1					1
KERN	2,075		2,227	4,083	3,603	71	67	433 12,559
KINGS	280		232	551	337	12	76	54 1,542
KLAMATH	1							1
KOOTENAI			1					1
LAKE	670		176	640	495	4	7	48 2,040
LASSEN	141		29	165	43		1	10 389
LOS ANGELES	8,010		14,705	20,769	18,711	270	90	14,639 77,194
MADERA	288		285	510	177	4	13	33 1,310
MADISON					1			1
MARICOPA		1		1	2		1	5
MARIN	603		171	1,010	105	3	5	173 2,070
MARIPOSA	140		37	106	30		8	5 326
MENDOCINO	896		172	819	624	6	6	50 2,573
MERCED	756		495	1,587	1,319	18	3	115 4,293
MINNEHAHA				1				1
MODOC	50		6	53	18	1	4	132
MONO	74		4	62	20	2	1	5 168
MONTEREY	1,604		604	2,160	1,015	7	31	105 5,526
NAPA	517		229	784	931	23	12	208 2,704
NEVADA	936		337	1,038	526	4	14	104 2,959
OKLAHOMA	1							1
ORANGE	3,071		4,911	8,372	10,026	89	37	1,342 27,848
OTTAWA				1				1
PALM BEACH				1				1
PASCO				1				1
PENNINGTON					1			1
PIMA			1	1				2

PINAL			1					1
PLACER	1,316	1,235	4,017	1,110	17	75	2,364	10,134
PLUMAS	167	18	119	37		4	1	346
RICHLAND			1					1
RIVERSIDE	3,271	6,531	8,004	15,212	736	251	1,023	35,028
SACRAMENTO	2,597	4,026	10,552	5,850	110	123	2,945	26,203
SAN BENITO	300	46	578	113	3	2	24	1,066
SAN BERNARDINO	1,649	6,341	6,887	11,636	240	71	608	27,432
SAN DIEGO	4,675	6,069	12,076	6,528	131	639	1,146	31,264
SAN FRANCISCO	496	827	2,276	140	7	3	333	4,082
SAN JOAQUIN	1,776	2,401	5,280	1,923	124	48	962	12,514
SAN LUIS OBISPO	2,019	955	2,743	895	11	19	159	6,801
SAN MATEO	815	882	2,690	656	4	5	242	5,294
SANTA BARBARA	1,544	516	2,219	1,050	21	23	434	5,807
SANTA CLARA	1,839	1,702	8,741	1,355	42	19	710	14,408
SANTA CRUZ	1,262	393	1,513	925	5	4	104	4,206
SHASTA	1,509	262	1,658	496	6	15	57	4,003
SIERRA	24	5	26	14			3	72
SISKIYOU	502	69	384	160	1	5	11	1,132
SNOHOMISH			1					1
SOLANO	988	494	2,281	1,641	20	104	372	5,900
SONOMA	1,862	832	2,430	3,279	82	23	704	9,212
STANISLAUS	1,154	1,419	2,895	3,280	103	20	715	9,586
SUTTER	557	150	982	834	18	15	100	2,656
TEHAMA	482	113	569	308	4	7	42	1,525
THURSTON			1					1
TRINITY	149	17	102	58	1	3	4	334
TULARE	909	827	1,587	1,000	17	18	118	4,476
TUOLUMNE	641	115	667	221	15	8	32	1,699
VENTURA	2,178	1,791	4,326	1,680	15	75	300	10,365
WASCO	1							1
WASHINGTON			1					1
WASHOE	1		1				1	3
WORCESTER						1		1
YAVAPAI			1					1
YOLO	581	555	1,970	1,010	15	17	194	4,342
YUBA	405	124	632	542	9	26	122	1,860
Grand Total	65,903	70,688	154,125	111,326	2,445	2,171	36,779	443,437

Exhibit 4

county	Sum of Results
LOS ANGELES	3194
SAN DIEGO	1265
RIVERSIDE	529
SAN LUIS OBISPO	73
FRESNO	277
CONTRA COSTA	481
SACRAMENTO	484
ORANGE	1311
VENTURA	309
SAN BERNARDINO	529
IMPERIAL	18
SANTA BARBARA	228
TULARE	85
KERN	95
INYO	4
MONTEREY	38
SAN MATEO	198
SANTA CLARA	970
SAN FRANCISCO	419
SOLANO	176
ALAMEDA	663
NAPA	49
MARIN	211
SANTA CRUZ	133
SAN JOAQUIN	148
CALAVERAS	8
MERCED	24
STANISLAUS	278
TUOLUMNE	48
SONOMA	276
MENDOCINO	18
LAKE	1
HUMBOLDT	74
DEL NORTE	2
PLACER	200
YOLO	28
EL DORADO	19
YUBA	20
BUTTE	120
NEVADA	79
PLUMAS	2
SUTTER	20
SHASTA	72

Exhibit 5

county	Sum of Results
LOS ANGELES	1758
SAN DIEGO	1032
RIVERSIDE	303
SAN LUIS OBISPO	5
FRESNO	80
CONTRA COSTA	42
SACRAMENTO	477
ORANGE	1300
VENTURA	62
SAN BERNARDINO	293
SANTA BARBARA	97
TULARE	8
KERN	112
INYO	3
MONTEREY	65
SAN MATEO	597
SANTA CLARA	867
SAN FRANCISCO	591
SOLANO	8
ALAMEDA	181
NAPA	14
MARIN	7
SANTA CRUZ	12
SAN JOAQUIN	18
CALAVERAS	2
MERCED	3
STANISLAUS	32
TUOLUMNE	2
SONOMA	19
MENDOCINO	10
PLACER	103
YOLO	3
EL DORADO	1
BUTTE	2
SUTTER	1
SHASTA	28

User	License #	Documentation Type
Adeyemo, Debo	MTA00040111	California state laboratory personnel license
Au, Toan	MTA00041727	California state laboratory personnel license
Barranta, Chester	MTP00000396	California state laboratory personnel license
Bautista, Kathleen Mae	MTP02012240	California state laboratory personnel license
Bertuccelli, Zeba	MTP01015784	California state laboratory personnel license
Braley, Matt	MTP01008967	California state laboratory personnel license
Castillo, Kathleen	MTA00045624	California state laboratory personnel license
Chan, Adrian	MTP01007257	California state laboratory personnel license
Chan, Cindy	MTP00000485	California state laboratory personnel license
Chen, Diana	MTP02030492	California state laboratory personnel license
Chen, Irene	MTA00030957	California state laboratory personnel license
Cheng, Amy	MTA00041542	California state laboratory personnel license
de la Rama, Shirley	MTA00041632	California state laboratory personnel license
dela Resma, Erin	MTP02013365	California state laboratory personnel license
DelosReyes, Brandon	MTP02023229	California state laboratory personnel license
Dockery, Eva	MTA02045639	California state laboratory personnel license
Dsouza, Cheryl	MTA00041476	California state laboratory personnel license
Flores, Edward	MTA00044893	California state laboratory personnel license
Fong, Wallace	MTA01011845	California state laboratory personnel license
Ford, Audrey	MTP00000548	California state laboratory personnel license
Foshay, Kelly	MTA00044563	California state laboratory personnel license
Gorman, Kimberly Lung	MTP00000455	California state laboratory personnel license
Huang, Annie	MTA02032031	California state laboratory personnel license
Huang, Chelsea	MTP02211775	California state laboratory personnel license
Japson, Arlene	MTA00038849	California state laboratory personnel license
Junio, Jermaund	MTA01014366	California state laboratory personnel license
Kan, Ricky	MTP02292599	California state laboratory personnel license
Le, Lien	MTA00041967	California state laboratory personnel license
Lu, Valery	MTP02206715	California state laboratory personnel license
Marcelo, Marlon	MTA00041197	California state laboratory personnel license
McLean, Sarah	MTA00044912	California state laboratory personnel license
Mon, May Myat	MTP02292682	California state laboratory personnel license
Mondala, Jessie	MTA00039044	California state laboratory personnel license
Nakamura, Izumi	MTP00000188	California state laboratory personnel license
Nguyen, Billy	MTP00000399	California state laboratory personnel license
Nguyen, Chau	MTA02014081	California state laboratory personnel license
Nguyen, Chi	MTA00043731	California state laboratory personnel license
Nguyen, Emily	MTA02006086	California state laboratory personnel license
Nguyen, Jane	MTA00041749	California state laboratory personnel license
Nguyen, Long	MTA00043151	California state laboratory personnel license
Nguyen, Teresa	MTA01000931	California state laboratory personnel license
Padmanaban, Preethi	MTP02030699	California state laboratory personnel license
Paragas, Daniel	MTA00040638	California state laboratory personnel license

Pena, Laura	MTA00044955	California state laboratory personnel license
Pham, Sukie	MTA00043059	California state laboratory personnel license
Phan, Tu	MTP01008050	California state laboratory personnel license
Pouono, Sean	MTA00045530	California state laboratory personnel license
Sabalvaro, Camille	MTP01003590	California state laboratory personnel license
Saccardi, Stephanie	MTP02013283	California state laboratory personnel license
Savinov, Lev	MTA00041633	California state laboratory personnel license
Takiar, Aditi	MTP00000550	California state laboratory personnel license
Ton, Phung	MTP02143899	California state laboratory personnel license
Vehouni, Suzie	MTA00038207	California state laboratory personnel license
Volkova, Ilona	MTA00044023	California state laboratory personnel license
Yee, Lisa	MTP01015189	California state laboratory personnel license
Yuen, Kenneth	MTP02030170	California state laboratory personnel license
Zhu, Betty	MTA01008462	California state laboratory personnel license

Legal name EXAS	Legal name acquisition	Type of transaction	Description	Date closed
Exact Sciences Corporation	Sampleminded, Inc.	Acquisition	Sampleminded was a software company that built and maintained the custom lab information management system (LIMS) for Cologuard. Exact Sciences was their primary customer and with the scaling up of launch, securing this vendor and bringing the talent in house became critical.	8/1/2017
Exact Sciences Corporation	Armune Biosciences, Inc.	Asset purchase	Armune held an IP license from the University of Michigan for protein markers. The purpose of the acquisition was to acquire these IP rights for discovery efforts for pipeline programs.	12/15/2017
Exact Sciences Corporation	Biomatrica, Inc.	Acquisition	Biomatrica developed LBgard, the blood tube used in Exact Sciences blood-based tests. LBgard uses a proprietary, trade secret buffer in the tube for stabilizing cfDNA.	10/2/2018
Exact Sciences Corporation	Genomic Health, Inc.	Acquisition	Genomic Health, Inc. had developed and commercialized best-in-class Oncotype DX assets across breast, prostate, and colon cancer. Exact Sciences purchased Genomic Health for the rights to those products.	11/8/2019
Exact Sciences Corporation	Paradigm Diagnostics, Inc.	Acquisition	Paradigm offers a comprehensive genomic profiling test for patients with advanced, refractory, or recurrent cancer, allowing physicians to better understand a patient's tumor profile and more effectively recommend targeted therapies or clinical trials. The test is differentiated from other tests by a design that requires smaller sample requirements and delivers faster results.	3/3/2020
Exact Sciences Corporation	Viomics, Inc.	Acquisition	Viomics provides extensive sequencing capabilities and expertise in identifying unique biomarkers that indicate the presence of cancer in solid tissue and blood.	3/3/2020
Exact Sciences Corporation	Base Genomics Ltd.	Acquisition	Base Genomics developed the TAPS technology to replace the bisulfite conversion step in DNA sequencing. This permits the simultaneous analysis of genomic and methylomic data for cancer and other types of testing.	10/25/2020
Exact Sciences Corporation	Thrive Earlier Detection Corp.	Acquisition	Thrive was and is developing a test for multi-cancer early detection (MCED) from a simple blood draw. This test is now in early stages of commercialization via the Exact Sciences sales force.	1/5/2021
Exact Sciences Corporation	Ashion Analytics LLC	Acquisition	Comprehensive genomic profiling test (late stage therapy selection, solid tumors, whole exome technology), and molecular residual disease development support.	4/14/2021
Exact Sciences Corporation	PreventionGenetics LLC	Acquisition	Broad portfolio of genetic tests including hereditary cancer and various rare diseases	1/9/2022
Exact Sciences Corporation	OmicEra Diagnostics, GmbH	Acquisition	Proteomics-focused diagnostics company supporting biomarker discovery and translational research.	5/2/2022
Exact Sciences Corporation	PFS Genomics, Inc.	Acquisition	Gene expression signature to predict whether early-stage invasive breast cancer patients treated with breast-conserving surgery are likely to benefit from additional radiotherapy.	6/23/2023
Exact Sciences Corporation	Resolution Bioscience, LLC	Asset purchase	Liquid biopsy therapy selection testing (NGS-based precision oncology solutions)	9/12/2023
Exact Sciences Corporation	TwinStrand Biosciences, Inc.	Exclusive license	Duplex Sequencing error-correction technology for ultra-high accuracy NGS, ideal for detecting ultra-low-frequency mutations	7/21/2024
Exact Sciences Corporation	Freenome Holdings, Inc.	Exclusive license	Blood-based colorectal cancer screening test utilizing NGS and proteins.	11/10/2025